• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method.利用SYFPEITHI结合多项式方法预测肝癌特异性HLA - A2限制性CTL表位
World J Gastroenterol. 2005 Jan 14;11(2):208-11. doi: 10.3748/wjg.v11.i2.208.
2
[Prediction synthesis and identification of HLA-A2-restricted cytotoxic T lymphocyte epitopes of the tumor antigen MAGE-n].[肿瘤抗原MAGE-n的HLA - A2限制性细胞毒性T淋巴细胞表位的预测合成与鉴定]
Zhonghua Yi Xue Za Zhi. 2003 Jun 25;83(12):1080-3.
3
Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma.人肝细胞癌MAGE-n基因编码的HLA - A2限制性CTL表位的鉴定
Cancer Biol Ther. 2004 Sep;3(9):891-8. doi: 10.4161/cbt.3.9.1081. Epub 2004 Sep 15.
4
Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.在肝细胞癌患者中,外周血中识别野生型p53衍生表位的CD8 + T淋巴细胞频率增加与表位缺失肿瘤变体的存在相关。
Int J Cancer. 2006 Dec 15;119(12):2851-60. doi: 10.1002/ijc.22251.
5
Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.肝素酶的肽 FLNPDVLDI 是一种新型的 HLA-A2 限制性 CTL 表位,通过 8 臂设计在体外具有强大的免疫抗肿瘤作用。
Oncol Rep. 2013 May;29(5):1955-61. doi: 10.3892/or.2013.2347. Epub 2013 Mar 13.
6
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.鉴定可能对肝细胞癌的磷脂酰肌醇蛋白聚糖-3特异性免疫治疗有用的HLA-A2或HLA-A24限制性CTL表位。
Clin Cancer Res. 2006 May 1;12(9):2689-97. doi: 10.1158/1078-0432.CCR-05-2267.
7
Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.鉴定新型 HLA-A2 限制性突变 Survivin 表位,并诱导能够有效交叉识别野生型 Survivin 抗原的特异性抗 HCC CTL。
Cancer Immunol Immunother. 2013 Feb;62(2):393-403. doi: 10.1007/s00262-012-1323-4. Epub 2012 Aug 29.
8
Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.利用 HLA-A2 限制性 MAGE-n 肽在体外高效诱导针对肝细胞癌的细胞毒性 T 淋巴细胞
Cancer Lett. 2004 Aug 10;211(2):219-25. doi: 10.1016/j.canlet.2004.02.013.
9
Prediction and preliminary screening of HLA-A*0201-restricted epitope peptides of human GPC3.人GPC3的HLA-A*0201限制性表位肽的预测与初步筛选
Int J Immunogenet. 2016 Jun;43(3):166-70. doi: 10.1111/iji.12260. Epub 2016 Apr 22.
10
Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.在HLA转基因小鼠中评估共表达HLA-A2/H-2kb和CTL多表位的基于表位疫苗与B16细胞系的抗肿瘤免疫功效。
Vaccine. 2007 Jun 15;25(25):4853-60. doi: 10.1016/j.vaccine.2006.12.029. Epub 2006 Dec 28.

引用本文的文献

1
FANCA promotes lung adenocarcinoma progression and is a potential target for epitope vaccine immunotherapy.FANCA 促进肺腺癌的进展,是表位疫苗免疫治疗的潜在靶点。
J Transl Med. 2024 Oct 7;22(1):911. doi: 10.1186/s12967-024-05675-w.
2
Peptides of a Feather: How Computation Is Taking Peptide Therapeutics under Its Wing.羽毛同源的肽:计算如何为肽治疗学提供支持。
Genes (Basel). 2023 May 29;14(6):1194. doi: 10.3390/genes14061194.

本文引用的文献

1
Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.利用 HLA-A2 限制性 MAGE-n 肽在体外高效诱导针对肝细胞癌的细胞毒性 T 淋巴细胞
Cancer Lett. 2004 Aug 10;211(2):219-25. doi: 10.1016/j.canlet.2004.02.013.
2
Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.慢性丙型肝炎患者肝细胞癌的筛查试验:一项系统评价
Hepatology. 2002 Nov;36(5 Suppl 1):S84-92. doi: 10.1053/jhep.2002.36817.
3
Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells.用自体肿瘤脉冲树突状细胞治疗不可切除的肝细胞癌。
J Gastroenterol Hepatol. 2002 Aug;17(8):889-96. doi: 10.1046/j.1440-1746.2002.02817.x.
4
Immunotherapy of hepatocellular carcinoma.肝细胞癌的免疫治疗
Expert Opin Biol Ther. 2002 Feb;2(2):123-33. doi: 10.1517/14712598.2.2.123.
5
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.复发性尤因肉瘤和肺泡横纹肌肉瘤患者肿瘤特异性肽疫苗接种与持续输注白细胞介素-2的试点试验:一项美国国立卫生研究院的机构间研究。
Med Pediatr Oncol. 2002 Mar;38(3):158-64. doi: 10.1002/mpo.1303.
6
Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients.肝细胞癌患者血清中p53抗原及抗p53抗体的临床意义
J Gastroenterol. 2001 Dec;36(12):830-6. doi: 10.1007/s005350170005.
7
A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.通过质谱鉴定的一种MAGE-A1 HLA-A A*0201表位。
Cancer Res. 2001 May 15;61(10):4072-7.
8
A listing of human tumor antigens recognized by T cells.一份被T细胞识别的人类肿瘤抗原清单。
Cancer Immunol Immunother. 2001 Mar;50(1):3-15. doi: 10.1007/s002620000169.
9
T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.T细胞对源自人甲胎蛋白的HLA-A*0201限制性肽段的反应。
J Immunol. 2001 Apr 15;166(8):5300-8. doi: 10.4049/jimmunol.166.8.5300.
10
Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach.通过一种新型的非T细胞依赖方法鉴定肿瘤相关的MHC I类配体。
Eur J Immunol. 2000 Aug;30(8):2216-25. doi: 10.1002/1521-4141(2000)30:8<2216::AID-IMMU2216>3.0.CO;2-7.

利用SYFPEITHI结合多项式方法预测肝癌特异性HLA - A2限制性CTL表位

Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method.

作者信息

Dong Hai-Long, Sui Yan-Fang

机构信息

Department of Pathology, Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China.

出版信息

World J Gastroenterol. 2005 Jan 14;11(2):208-11. doi: 10.3748/wjg.v11.i2.208.

DOI:10.3748/wjg.v11.i2.208
PMID:15633217
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4205403/
Abstract

AIM

To predict the HLA-A2-restricted CTL epitopes of tumor antigens associated with hepatocellular carcinoma (HCC).

METHODS

MAGE-1, MAGE-3, MAGE-8, P53 and AFP were selected as objective antigens in this study for the close association with HCC. The HLA-A*0201 restricted CTL epitopes of objective tumor antigens were predicted by SYFPEITHI prediction method combined with the polynomial quantitative motifs method. The threshold of polynomial scores was set to -24.

RESULTS

The SYFPEITHI prediction values of all possible nonamers of a given protein sequence were added together and the ten high-scoring peptides of each protein were chosen for further analysis in primary prediction. Thirty-five candidates of CTL epitopes (nonamers) derived from the primary prediction results were selected by analyzing with the polynomial method and compared with reported CTL epitopes.

CONCLUSION

The combination of SYFPEITHI prediction method and polynomial method can improve the prediction efficiency and accuracy. These nonamers may be useful in the design of therapeutic peptide vaccine for HCC and as immunotherapeutic strategies against HCC after identified by immunology experiment.

摘要

目的

预测与肝细胞癌(HCC)相关的肿瘤抗原的HLA - A2限制性CTL表位。

方法

本研究选择MAGE - 1、MAGE - 3、MAGE - 8、P53和AFP作为与HCC密切相关的目标抗原。采用SYFPEITHI预测方法结合多项式定量基序方法预测目标肿瘤抗原的HLA - A*0201限制性CTL表位。多项式得分阈值设定为 - 24。

结果

将给定蛋白质序列的所有可能九聚体的SYFPEITHI预测值相加,在初步预测中选择每种蛋白质得分最高的十个肽段进行进一步分析。通过多项式方法分析从初步预测结果中筛选出35个CTL表位(九聚体)候选序列,并与已报道的CTL表位进行比较。

结论

SYFPEITHI预测方法与多项式方法相结合可提高预测效率和准确性。这些九聚体在经免疫学实验鉴定后,可能有助于设计HCC治疗性肽疫苗以及作为针对HCC的免疫治疗策略。